Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development expenses	$ (6,541)	$ (7,999)	$ (12,932)	$ (14,202)
Less: participation by the Israeli Innovation Authority (IIA), Horizon 2020 and other parties	34	22	72	287
Research and development expenses, net	(6,507)	(7,977)	(12,860)	(13,915)
General and administrative expenses	(4,288)	(5,097)	(9,376)	(7,896)
Operating loss	(10,795)	(13,074)	(22,236)	(21,811)
Financial income	156	646	419	947
Financial expenses	(301)	(126)	(555)	(179)
Financial income (expenses), net	(145)	520	(136)	768
Net loss	$ (10,940)	$ (12,554)	$ (22,372)	$ (21,043)
Loss per share:
Basic and diluted net loss per share (in Dollars per share)	$ (0.34)	$ (0.49)	$ (0.7)	$ (0.82)
Weighted average number of shares used in computing basic and diluted net loss per share (in Shares)	32,136,352	25,662,752	32,068,271	25,599,008